1. The urinary F1 activation peptide of prothrombin is the predominant protein incorporated into calcium oxalate crystals precipitated from human urine. The aim of this study was to examine the effect of pure urinary prothrombin F1 on calcium oxalate crystallization in human urine. 2. Urinary prothrombin F1 was purified from demineralized calcium oxalate crystals precipitated from human urine, and its effects on calcium oxalate crystallization induced by addition of an oxalate load were tested in undiluted, ultrafiltered urine from healthy men, at final concentrations of 0 to 10 mgjl. 3. Urinary prothrombin F1 did not affect the amount of oxalate required to induce crystallization, but the volume of material deposited increased in proportion to increasing concentrations of urinary prothrombin Fl. However, the mean particle size decreased in reverse order: this was confirmed by scanning electron microscopy, which showed it to be the result of a reduction in crystal aggregation rather than in the size of individual crystals. Analysis of 14C-oxalate data revealed a dose-dependent decrease in calcium oxalate deposition with an increase in urinary prothrombin F1 concentration, indicating that the increase in particle volume recorded by the Coulter Counter resulted from inclusion of urinary prothrombin F1 into the crystalline architecture, rather than increased deposition of calcium oxalate. 4. It was concluded that urinary prothrombin F1 may be an important macromolecular determinant of stone formation.
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INTRODUCTION
A possible role for urinary proteins in the genesis of kidney stones was proposed more tha~30 yea~s ago when it was shown that the orga~llc matnx known to be present in all renal calcuh [1] consisted principally of protein [2] . However, in the absence of any conclusive evidence to confirm or refute the existence of such a role, urinary proteins were largely ignored in this respect, until more recently, when the advent of more sophisticated techniques for isolating, purifying, analysing and characterizing proteins, rekindled interest in the possibility that they may influence the course of stone disease. To avoid the well-recognized difficulties associated with studying the proteins of stone matrix [3] , several investigators have focused on those present in calcium oxalate (CaOx) crystals newly precipitated from fresh human urine [3] [4] [5] . These studies indicated that, despite the hundreds of proteins known to be present in human urine, relatively few actually participate directly in the nucleation and growth of CaOx crystals: the organic matrix of such crystals contains only specific urinary proteins. The selectivity of the inclusion of the~e proteins into the organic matrix of such crystals .IS demonstrated by the fact that they are present m quantities apparently unrelated to their abunda~~e in the urine from which the crystals were precipitated. For instance, the most plentiful protein in human urine, Tamm-Horsfall glycoprotein (THG), if present in the matrix at all, is detectable in only very minor amounts [3] . On the other hand, one particular protein is present in quantities which exceed those of all others, and which belie its low concentration in urine. Originally named crystal matrix protein, because early studies were unable to demonstrate its identity with known urinary proteins [3] , it is now known as urinary prothrombin Fl (UPTFl), after the demonstration of its relationship to human prothrombin [6, 7] and, more recently, confirmation of its close identity .with the Fl activation peptide of human prothrombin [8, 9] .
The fact that UPTFI is the principal component of CaOx crystal matrix extract (CME), which is a potent inhibitor of CaOx crystal growth and aggre- gation in urine [10] , its presence in human kidney stones [8, 9] and its precise distribution within the human nephron [II] , suggests that under normal physiological conditions it may fulfil a determinant function as an inhibitor of CaOx crystallization, and thereby of stone formation. However, to date, it has not been possible to obtain experimental evidence to support this hypothesis, because insufficient protein has been available to determine whether it can account for the inhibitory potency of the organic matrix of CaOx crystals. The aim of this study was to isolate and purify UPTFI from human urine in quantities large enough to allow the measurement of its inhibitory effect on CaOx crystallization in undiluted urine in vitro.
MATERIALS AND METHODS
Preparation of CME Collection and preparation of urine samples. Urine samples (24 h) were collected from healthy men who had no history of kidney stone disease. The samples were refrigerated during the collection period and during storage before use. Absence of blood from the specimens was confirmed using Multistix test strips (Miles Laboratories, Mulgrave, Victoria, Australia). The samples were pooled and centrifuged at 80001: for 15 min at 20°C in a Beckman 12-21 M/E centrifuge (Beckman Instruments, Palo Alto, CA, U.S.A.). The supernatant was filtered through O.22flm Millipore filters (# GVWP 14250, Millipore Corporation, Bedford, MA, U.S.A.).
Generation of CaOx crystals. Ca Ox crystals were precipitated from the pooled urine as previously described [3] . Briefly, the metastable limit of the urine with respect to CaOx, i.e. the minimum amount of oxalate required to elicit spontaneous detectable CaOx crystallization using the Coulter Counter, was first determined by titration with sodium oxalate solution. A standard load of oxalate (30flmo1/100ml urine) in excess of the metastable limit was then added with continuous stirring to the sample in 51 volumetric glass flasks, and the flasks were shaken at 900pm in a water bath heated to 37°C. To increase the yield of crystals, the same amount of sodium oxalate solution was added after I h and again after 2 h. The total incubation time was 4h.
The crystals were harvested by filtration through 0.22 flm Millipore filters and washed thoroughly with 0.1 mol/l sodium hydroxide followed by distilled water (Permutit Australia, Brookvale, NSW, Australia). They were then lyophilized and weighed.
Purification of UPTFI
To every I g of CaOx crystals was added 100ml of 0.25 mol/I EDTA solution (pH 8.0), and the suspension was stirred at room temperature until crystals were no longer detectable by light microscopy. The resulting CME, prepared from several batches of urine, was pooled, lyophilized and dissolved in 25 mmol/l Tris-HCI butTer (pH 7.3). It was then applied to a Bio-Gel P-6 DG desalting column, which was developed with the same butTer. The protein peak was collected manually and a small sample was subjected to an analytical run on reversed-phase HPLC using a Brownlee RP-300 microbore column (2.1 mm x 100 mm). A 30 min linear gradient was developed from 0 to 100% B, where solvent A was 0.1% aqueous trifluoroacetic acid and solvent B was 0.09% trifluoroacetic acid in 60% acetonitrile, 40% water. The column temperature was ambient (approximately 21DC) and the flow rate was 0.2 ml/min, The eluant was monitored by absorbance at 215 nm. The protein peak corresponding to what was presumed to be UPTFI on the basis of its relative retention behaviour [6] was collected and analysed by SDS/PAGE, which confirmed that the sample consisted almost exclusively of a single band of UPTFI, as judged by its molecular mass of 31 kDa. A larger, preparative reversed-phase HPLC run was then performed with the remainder of the sample from the desalting column, using identical conditions to those described for the analytical run, except that a Vydac C4 preparative column (lOmm x lOOmm) was used with a flow rate of 10 ml/min. Fractions were collected at I min intervals. The fractions known to contain UPTF1 were collected and dialysed extensively against phosphate butTer (pH 7.3), containing NaCi 8.5 gil, K 2HP04 1.43 gil and KH 2P04 0.25 gil, at 4°C and the protein concentration was determined using the fluorescamine method described by Bohlen et al. [12] and modified by Castell et al. [13] . The proteins were hydrolysed by autoc1aving in I mol/l NaOH at 120°C for 70 min before the assay. Both BSA and a-lactalbumin were used as standards.
50S/PAGE
The samples to be analysed were reduced with 2-mercaptoethanol and electrophoresed in 1 mmthick, 10-20% linear gradient gels on a Bio-Rad Mini-Protean II apparatus as previously described [3] , using the method based on principles established by Laemmli [14] . The gels were subsequently stained with silver [15] .
Determination of inhibitory activity
Urine samples (24 h) were collected from five healthy men, and were pooled, centrifuged and filtered as described above. Sodium azide was added at a final concentration of 0.025% and a portion was retained as a control (centrifuged and filtered sample). This control contained its full complement of macromolecules other than THG, which is known to be removed from urine by centrifugation and filtration [16, 17] . The remaining urine was ultrafiltered (nominal molecular mass cut-off of 10kOa) using an Amicon hollow fibre bundle (HI PIO-20; Amicon Corporation, Lexington, MA, U.S.A.) and divided into aliquots, to which purified UPTFI was added at final concentrations of 0, 1.0, 2.5 and 10mg/l. Inhibitory activity was assessed as previously described [18] . The metastable limit of all the portions was determined by titrating 4 ml samples with sodium oxalate solution as described above, using the Coulter Counter to detect crystals > 2 J-lm. Once the metastable limit had been determined, a standard load of oxalate (30 J-lmoljl00ml) in excess of this amount was added dropwise to the samples which were then incubated in a shaking water bath at 37°C for 120min. Crystal size distributions were measured at 30 min intervals using the Coulter Counter, and from these were calculated the total volumes of particulate material precipitated during the incubation period and the modes of the volume-size distribution curves. Because quantities of purified UPTFI were limited, each experiment could only be performed in duplicate; results are expressed as the mean of the two measured values.
Because preliminary studies had confirmed that UPTFI did not precipitate during the course of the experiment, control flasks containing all components other than oxalate were not included to account for possible counting interference caused by precipitated protein.
Scanning electron microscopy
At the end of each experiment, 2 ml aliquots were filtered (0.22 J-lm filters) and the filters were dried overnight at 37°C, after which they were mounted on aluminium stubs and gold-spluttered for 180s (SEM Autocoating Unit E5200, Polaron Equipment Ltd, Watford, U.K.). Stubs were examined using an ETEC Auto Scan Electron Microscope (Siemens AG, Karlsruhe, Germany) at an operating voltage of 20 kV, with the operator blinded with regard to the experimental source of the crystals.
Measurement of CaOx deposition by '4C-oxalate
There are recognized limitations associated with using the Coulter Counter to determine the volume of particles, especially if those particles consist of crystal aggregates: the Coulter Counter will record the interstices between individual crystals as solid crystalline material. Any error this may cause will be compounded by the fact that the total volume of crystals precipitated from urine comprises solid CaOx as well as urinary macromolecules, including UPTFl, trapped inside the crystalline architecture [10] . Furthermore, the Coulter Counter measures particles whose sizes fall within specified limits; crystals falling outside this size range (2-25.4 J-lm in these experiments) will not be counted by the instrument. Therefore, to determine whether particle volume accurately reflected the increase in crystal mass, parallel incubations were carried out with samples containing 14C-oxalate. In these samples, any decrease in soluble radioactivity must reflect precipitation of CaOx.
The radioactive samples were treated identically to the ones described above, except that 14C-oxalic acid (l0 J-lCij100ml) was added before induction of CaOx crystallization by addition of the oxalate load. At 30 min intervals, 1.0ml samples were filtered (0.22 J-lm) into 100J-li of concentrated HCl using a disposable syringe and filter holder. Filtration into acid was a precaution against the possibility that further precipitation of CaOx might occur after filtration of the solution. Duplicate 0.3 ml portions of the acidic solution were then added to 10ml of Ready Safe (Beckman Instruments) and counted for 5 min in a liquidscintillation counter (Beckman LS 3801 Liquid Scintillation System). Once again, each experiment was performed in duplicate and the results are expressed as mean values.
Ethical considerations
This study involved collection of urine samples from healthy control subjects, and was reviewed and approved by the Committee on Clinical Investigation (Ethics Committee) of the Flinders Medical Centre (minute no. 3024.12, 1993).
RESULTS
CME and purification of crystal matrix protein Figure 1 shows the SOS/PAGE electrophoretogram of the pooled desalted CME. Note that although the predominant protein band is UPTFI, with an apparent molecular mass of 30 kOa, other bands are also visible, including urinary human serum albumin (HSA) with an apparent molecular mass of 67 kOa and other, as yet unidentified, proteins. Figure 2 shows the elution profile of the extract after reversed-phase HPLC, which reveals the presence of two major peaks, the larger of which was shown to be urinary albumin by immunoblotting with an anti-HSA antibody, as well as a number of minor peaks, confirming the SOS/PAGE findings. Figure 3 shows the SOS/PAGE analysis of the peak corresponding to UPTFl, demonstrating that it contained almost pure UPTF1. It was therefore used in the inhibition experiments without further purification.
Effect of UPTFI on the urinary metastable limit with respect to CaOx. The minimum amount of oxalate required to elicit spontaneous detectable CaOx crystal nucleation was unaltered by ultrafiltration and by addition of increasing amounts of UPTFI up to and including a final concentration of IOmg/1. Therefore, an identical oxalate load was added to all the samples to induce CaOx crystallization. Effect of UPTF I on particle volume Figure 4 shows the time course of total particle volumes precipitated during the 120min incubation period after addition of oxalate load to the centrifuged and filtered control and the ultrafiltered urine samples containing varying amounts of UPTFI. In all cases, there was an initial lag phase, followed by a period of near-linear volume deposition which then approached a plateau. It is noteworthy that from zero time, the results for the centrifuged and filtered urine differed markedly from those obtained for all the ultrafiltered urine samples, which were superimposable for the first 30 min and then barely distinguishable from each other up to 60 min. After Effect of UPTFI on particle size Figure 5 shows the size of the particles precipitated from the various urine samples, expressed as the modes of the volume distribution curves at the end of the 120min incubation period. The most notable feature of these results is that the position of the modes of the curves varied directly in response to the concentration of UPTFI in the ultrafiltered urine. Thus, the mean particle size in the ultrafiltered urine containing no UPTFI was 18.3 j.lm, and this decreased steadily to 14.2, 12.7 and 7.3 j.lm at corresponding UPTFI concentrations of 1.25, 2.5 and 10mg/l. It is remarkable that the size of the particles deposited from the ultrafiltered urine containing the highest concentration of UPTF1 (7.3 j.lm) was less than that of those precipitated from the centrifuged and filtered control urine (8.5 j.lm), which contained a normal complement of urinary macromolecules (including UPTF1) other than THG. These findings were confirmed by scanning electron microscopy. Figure 6 shows low-power scanning electron micrographs of crystals deposited from the centrifuged and filtered control and the ultrafiltered urine samples containing varying concentrations of UPTFl. Mainly CaOx dihydrate crystals were precipitated: those from the centrifuged and filtered urine tended to be single or clustered into small loose aggregates. This sample also showed the presence of precipitated organic material on the filter surface. In contrast, the crystals precipitated from the ultrafiltered urine containing no added UPTF1 were highly aggregated and no precipitated organic material was observed. The degree of aggregation of the precipitated crystals decreased in relation to increasing concentrations of UPTF1, indicating that the dose-dependent reduction in particle size occurring with increasing concentrations of UPTFI noted above, was the result of a decrease in the degree of crystal aggregation, rather than in the size of individual crystals. In fact, it was apparent from observation of a large number of crystal fields that the presence of UPTFI tended to be associated with some very large individual crystals, the number of which increased in proportion to the concentration of the protein. This is illustrated in the micrographs presented. Furthermore, the surfaces of most of the crystals precipitated in the presence of UPTF1, but particularly the larger ones, have a mottled or mosaic appearance: the effect is more obvious in samples containing high concentrations of UPTFl, especially at high magnification, as shown in Fig. 7 . This electron micrograph shows examples of the larger crystals precipitated from the plain ultrafiltered urine, that to which 10mg/1 UPTF1 had been added, and the same urine which had been simply centrifuged and filtered. Neither the crystals precipitated from the plain ultrafiltered urine nor those from the centrifuged and filtered urine exhibited the mosaic patterns seen on those from the ultrafiltered urine containing UPTFl. This suggests that, although the effect is probably the result of binding of macromolecules to the surfaces of the crystals, it can be attributed specifically to the binding of UPTF1, otherwise the pattern would have been observed on the crystals from the centrifuged and filtered urine. Figure 8 shows the time course of the disappearance of 14C-oxalate from the supernatants of the urine samples during the 120min incubation period after addition of the oxalate load. To normalize the data, the values are presented as the amount of 14C-oxalate remaining in solution, expressed as a percentage of the zero time value. There are two remarkable features. Firstly, the rate of disappearance of 14C-oxalate from the centrifuged and filtered urine was greater than in any of the ultrafiltered samples. Secondly, among the various ultrafiltered urine samples, the rate of reduction in 14C-oxalate decreased in proportion to increasing concentrations of UPTF1. It should be noted that the data demonstrate that the deposition of 14C-oxalate in the centrifuged and filtered urine was greater than in any of the ultrafiltered urine samples: at 120min, the mean amount of 14C-oxalate remaining in the control urine (51.1%) was less than that in the ultrafiltered urine containing no added UPTFI (59.4%). The corresponding values in the ultrafiltered urine samples containing UPTFI at final concentrations of 1.25, 2.5 and 10 mg/l were 74.0%, 78.4% and 77.8% respectively, corresponding to degrees of inhibition of CaOx deposition of 24.7%, 32.2% and 31.1% compared with ultrafiltered urine alone. This demonstrates that the dose-dependent increase in particle volume that was recorded by the Coulter Counter with increasing concentrations of UPTFI could not be attributed to increases in the deposition of CaOx. On the contrary, the 14C_ oxalate data indicate quite clearly that CaOx Fig. 6 . Low-power scanning electron micrographs of crystals precipitated in urine that had been centrifuged and filtered (labelled here as spun and filtered), and in portions of the same urine which had been ultrafiltered (UF) through hollow fibres with a nominal molecular mass cut-off of 10kDa and supplemented with 0, 1.0,2.5 and 10mg/i of UPTFI deposition is inhibited, not promoted, in proportion to the prevailing concentration of U PTF 1.
Measurement of CaOx deposition by 14C-oxalate

DISCUSSION
Previous studies have shown that UPTFI possesses all the characteristics expected of a urinary macromolecule fulfilling a directive function in CaOx stone pathogenesis. The protein is present in calcium stones [9] , is confined to specific, circumscribed regions of the human nephron [II] and is the principal protein present in the organic matrix of CaOx crystals precipitated from fresh human urine [3] . This organic matrix, CME, has been shown to be the most potent inhibitor of CaOx crystallization induced in human urine so far described [10] . However, although these features, collectively, suggest that UPTFI might be involved in controlling the crystallization of CaOx ill rioo, the evidence for its fulfilling such a function has been, at best, indirect, since the protein has not been available in sufficient quantities free of other macromolecular contaminants to test its inhibitory activity in urine. It was the object of this study to determine whether UPTFI purified from human urine could account for the observed potent inhibitory effect of CaOx crystal matrix on the nucleation, growth and aggregation of CaOx crystals in undiluted urine, and thereby, to establish whether the protein fulfils some function in stone formation.
UPTFI was isolated from CaOx crystals precipitated from male human urine in large-scale crystallization experiments using methods already established in our laboratory, and then purified from the pooled, demineralized extract of these crystals by reversed-phase HPLC to yield a homogeneous preparation that gave a single band on SDS/PAGE. This material was considered sufficiently pure to be used in the inhibition studies. The results of these experiments were unequivocal; UPTFI is a potent inhibitor of CaOx crystal growth and aggregation in undiluted urine, but like all macromolecules previously tested with the technique used here [10, [19] [20] [21] , did not affect the amount of oxalate required to induce detectable spontaneous nucleation of CaOx. Furthermore, as was shown previously with CME [10] , the volume of precipitated material increased in a dose-response fashion in the presence of the Fig. 7 . High-power scanning electron micrographs of the same crystals shown in Fig. 6 , derived from centrifuged and filtered urine and ultrafiltered (UF) urine containing 0 and 10mg!1 of UPTFI Fig. 8 . Percentage decrease in soluble "C-oxalate with time after the addition of the oxalate load in centrifuged and filtered urine, and in portions of the same urine which had been ultrafiltered at a nominal molecular masscut-off of 10kDa and supplemented with 0, 1.0, 2.5 and 10mg/i of UPTFI protein, despite the fact that the amount of 14C-oxalate decreased in exact reverse order. A similar, apparently contradictory observation has been reported before: CME significantly increased the volume of precipitated material, while having no effect on the deposition of 14C-oxalate [10] . In that instance, the observed increase in particle volume in the absence of a corresponding promotion of 14C-oxalate deposition, was attributed to the inclusion of urinary macromolecules into the crystalline architecture. It is apparent that although included organic material accounts for only a small proportion of a crystal's (and indeed a stone's) mass, nonetheless, it can occupy a significant volume of the structure. It is unlikely that the apparent discrepancy between the Coulter Counter and 14C-oxalate data observed in the present study can be attributed simply to shortcomings associated with the technique of particle size analysis, although this may have been partly responsible. The Coulter Counter estimates a particle's size on the basis of the volume of electrolyte it displaces as it traverses the counting orifice; it cannot distinguish between particles of different composition or density. Thus, a loosely aggregated cluster of crystals, though containing large lacunae filled with the urine in which it is suspended, will be recognized by the Coulter Counter simply as a large solid particle, thereby overestimating the volume of crystalline material in suspension. If this were the sole explanation for the apparent incompatibility between the volume and 14C-oxalate data, then we would have expected the measured volume to decrease as the degree of aggregation of the crystals reduced in relation to the concentration of UPTFl, not increase, as was observed. Thus, although drawbacks accompanying the Coulter Counter assessment of particle volume may partly account for the apparently inconsistent findings, a more probable explanation is that macromolecules trapped within the crystals occupy a significant proportion of the structure's volume and thereby increase its overall size. Certainly, this would explain the empirical observation of an increased number of large individual crystals precipitated from the urine samples containing UPTFI. Nonetheless, while UPTFI increased the overall bulk of particulate material precipitated, it effectively reduced the amount of CaOx deposited. UPTFI concentrations of 2.5 and lOmgjl inhibited the deposition of 14C-oxalate by approximately 30%. The protein is therefore an efficient inhibitor of crystal growth, where this is defined as the increase . . in size brought about specifically by the deposition upon the crystal surface of new solute ions, and in this respect it differs from other macromolecules whose effects on CaOx crystal growth in urine have been similarly measured. Although numerous studies have reported that a number of urinary proteins inhibit the deposition of CaOx from inorganic solutions [21] , to our knowledge, the only individual urinary proteins whose effects on CaOx crystallization have been tested in undiluted urine are HSA [21] and THG [21] [22] [23] , and of these, the effects of only THG have been measured using a combination of both Coulter Counter and 14C-oxalate analysis [23] . At a concentration of 20mg/l, HSA slightly, but significantly, increased the volume of CaOx precipitated [21] . This observation is in keeping with the fact that the protein is incorporated into CaOx crystals precipitated from urine, although in quantities less than might be expected, in view of its abundance in urine [3] . On the other hand, THG quite clearly promoted the deposition of CaOx at unusually high urine osmolalities [22, 23] , but had no effect at more common physiological osmolalities [23] . Thus, to date, no naturally occurring individual urinary protein, with the notable exception of UPTFl, nor indeed any mixture of proteins [10] , has been demonstrated to inhibit significantly the deposition of CaOx in undiluted urine. However, although UPTFI is the first urinary protein with demonstrable inhibitory effects on CaOx crystal growth, it is its effect on crystal aggregation that is likely to be of greater physiological relevance in the prevention of urolithiasis. Crystal aggregation is well recognized to be a crucial step in the formation of calculi, since it is the only process by which large particles can be formed in a short space of time. Over a concentration range of 1.25 to lOmg/I, UPTFI inhibited the aggregation of CaOx crystals that occurs upon removal of all macromolecules with molecular masses greater than IOkDa [19] [20] [21] 23] . The average size of the precipitated particles was reduced progressively from 18.3 JIm in the ultrafiltered urine to 14.2, 12.7 and 7.3 JIm at UPTFI concentrations of 1.25, 2.5 and 10 mg/l respectively. Most noteworthy, was the fact that the particle size was reduced to less than that of the particles precipitated from the centrifuged and filtered urine, indicating that the endogenous concentration of UPTFI in the particular centrifuged and filtered urine used in this study was less than 10 mg/l, as would be expected from published data. Using immunological techniques, Bezeaud and Guillin [24] reported that the normal concentration of Fl in urine ranged from 0.9 to 35.3 nmol/l, If we assume a molecular mass of F 1 of approximately 30 kDa, these figures convert to approximately 0.03 to 1.1 mg/l, which is very close to the value of 1.25 mg/l used in the present study, at which inhibitory effects on both crystal aggregation and 14C-oxalate deposition were clearly evident. UPTFI is therefore a powerful inhibitor of CaOx crystal aggregation in undiluted urine at concentrations of the order of those expected in normal urine, and may thus play an important role in the prevention of CaOx stone formation. Furthermore, the results of this study demonstrate that UPTFI probably accounts for the potent inhibition of crystal aggregation demonstrated by the organic matrix (CME) of CaOx crystals precipitated from urine [10] . Only one other protein, THG, has been shown to inhibit CaOx crystal aggregation in undiluted ultrafiltered urine [21, 23] , but even at a final concentration of 20 mg/l, it was unable to reverse the formation of large crystal aggregates that occurred upon ultrafiltration. Moreover, THG cannot account for the fact that large crystal aggregates do not form in centrifuged and filtered urine, because it is efficiently removed from urine by centrifugation and filtration [16, 17] . Furthermore, it is virtually absent from CME [3] .
The strong inhibitory effects of UPTFI on CaOx crystallization can probably be attributed to the presence of its Gla domain which is the region responsible for binding of the parent prothrombin molecule to phospholipid membranes during blood coagulation [25] . Although in the present study, the strong binding of UPTFI to CaOx was indirectly manifested as the reduction in 14C-oxalate deposition that occurred in the presence of the peptide, binding was clearly visible from the scanning electron micrographs of the precipitated crystals. These showed the presence of gross defects which appeared as irregular mottled variegations covering the crystal surfaces. Although visible on the smaller crystals, the effect was most marked and conspicuous on the surfaces of the larger crystals. By comparison, the margins of the crystals precipitated from the ultrafiltered urine containing no UPTFI were crisply delineated and the crystal surfaces appeared smooth and unmarked. Crystals deposited from the centrifuged and filtered urine, although lacking the clean uniformity of those from the ultrafiltered urine, and showing some obvious surface irregularities, nonetheless, did not exhibit the extreme mosaic appearance of those deposited in the presence of purified UPTFl, despite the fact that the urine from which they had been derived would have contained endogenous levels of the peptide. Thus, the results presented here strongly indicate that the exceptional inhibitory effects of UPTFI on CaOx crystal growth and aggregation, and its inclusion into those crystals, result directly from its exceptional binding affinity for their surfaces, the strength of which almost undoubtedly can be attributed to the y-carboxyglutamic acid residues of the protein's Gla domain. However, although it might be tempting to suppose that UPTFI, by virtue of its Gla domain, is the principal macromolecular inhibitor of CaOx crystal aggregation in urine, other published data highlight that such a conclusion cannot be drawn at the present time. Other urinary proteins, including nephrocalcin [26] , uropontin [27] and uronic-acid-rich protein (a close relative of inter-a-trypsin inhibitor) [28] have been shown to inhibit CaOx crystal growth in inorganic solutions. It is possible, therefore, that these proteins may also exert strong inhibitory effects in vivo, but this cannot be assumed at present because their effects on CaOx crystallization in undiluted human urine have never been tested.
Nonetheless, irrespective of any inhibitory properties of other urinary proteins that may ultimately be disclosed, the results of our investigation demonstrate that the urinary form of human prothrombin fragment 1, UPTF1, is a potent inhibitor of CaOx crystal growth and aggregation under conditions approximating those operating in vivo. This finding supports evidence already linking stone formation and blood coagulation [8, 9] , and reinforces the possibility that UPTFI may play a critical role in the prevention of urolithiasis.
